IPSEN (IPSEY)
(Delayed Data from OTC)
$30.06 USD
-0.30 (-0.99%)
Updated Apr 29, 2024 02:11 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
Price, Consensus and EPS Surprise
IPSEY 30.06 -0.30(-0.99%)
Will IPSEY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IPSEY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IPSEY
Is Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year?
Is IPSEN (IPSEY) Outperforming Other Medical Stocks This Year?
IPSEY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y
Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More
Epizyme (EPZM) Stock Surges on Acquisition Offer From Ipsen
Other News for IPSEY
Ipsen price target raised by EUR 2 at RBC Capital
Ipsen price target raised by EUR 2 at Deutsche Bank
Ipsen S.A. reports Q1 results; reaffirms full-year guidance
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
Ipsen, Skyhawk Therapeutics announce worldwide RNA targeting collaboration